Augurex - Model 14-3-3 - Augurex’s Autoimmune Disease Diagnostic Portfolio
14-3-3η is not normally present outside of cells. Therefore, in the disease state, the body views it as foreign and mounts an immune response in an attempt to clear it. This immune response generates14-3-3η specific auto-antibodies that are measureable in blood and provide complementary disease information to the 14-3-3η protein. In particular, they are highly specific in very early RA and increase the patient identification rate into the 90% range. Early RA diagnosis and treatment improves clinical outcomes and 14-3-3η protein and its auto-antibodies supports that clinical priority.
Product Details
Risk of RA
Diagnosis
- 14-3-3η is a Novel Mediator Associated with the Pathogenesis of Rheumatoid Arthritis and Joint Damage
- Review: 14-3-3η – a Novel Biomarker Platform for Rheumatoid Arthritis
- Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis
- 14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
- The Diagnostic Value of 14-3-3η Protein Levels in Patients with Rheumatoid Arthritis
- Serum 14-3-3η Protein is Associated with Clinical and Serologic Features of Sjögren’s Syndrome in Patients with Systemic Lupus Erythematosus: A Cross-Sectional Analysis
Prognosis
- Serum Levels of 14-3-3η Protein Supplement C-reactive Protein and Rheumatoid Arthritis-Associated Antibodies to Predict Clinical and Radiographic Outcomes in a Prospective Cohort of Patients with Recent-Onset Inflammatory Polyarthritis
- Impending Radiographic Erosive Progression Over the Following Year in a Cohort of Consecutive Patients with Inflammatory Polyarthritis: Prediction by Serum Biomarkers
Monitoring
- Serum 14-3-3η Level is Associated with Severity and Clinical Outcomes of Rheumatoid Arthritis, and its Pretreatment Level is Predictive of DAS28 Remission with Tocilizumab
- Decrease in 14-3-3η Protein Levels is Correlated with Improvement in Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib
- Correlation of Plasma 14-3-3η Levels with Disease Activity Measures in Methotrexate-Naïve RA Patients Treated with Upadacitinib Monotherapy in the Select-Early Phase 3 Study
Customer reviews
No reviews were found for Augurex - Model 14-3-3 - Augurex’s Autoimmune Disease Diagnostic Portfolio. Be the first to review!